AC IMMUNE SA (ACIU) Fundamental Analysis & Valuation

NASDAQ:ACIU • CH0329023102

Current stock price

3.15 USD
-0.17 (-5.12%)
Last:

This ACIU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ACIU Profitability Analysis

1.1 Basic Checks

  • In the past year ACIU has reported negative net income.
  • ACIU had a negative operating cash flow in the past year.
  • ACIU had negative earnings in each of the past 5 years.
  • ACIU had negative operating cash flow in 4 of the past 5 years.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • The Return On Assets of ACIU (-41.88%) is comparable to the rest of the industry.
  • The Return On Equity of ACIU (-115.10%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ACIU Health Analysis

2.1 Basic Checks

  • ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for ACIU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -3.24, we must say that ACIU is in the distress zone and has some risk of bankruptcy.
  • ACIU has a Altman-Z score (-3.24) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that ACIU is not too dependend on debt financing.
  • The Debt to Equity ratio of ACIU (0.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -3.24
ROIC/WACCN/A
WACC4.93%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 1.16 indicates that ACIU should not have too much problems paying its short term obligations.
  • ACIU has a Current ratio of 1.16. This is amonst the worse of the industry: ACIU underperforms 85.14% of its industry peers.
  • ACIU has a Quick Ratio of 1.16. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
  • ACIU has a Quick ratio of 1.16. This is amonst the worse of the industry: ACIU underperforms 84.56% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ACIU Growth Analysis

3.1 Past

  • ACIU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.69%.
EPS 1Y (TTM)-32.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.27%

3.2 Future

  • ACIU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.56% yearly.
  • ACIU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 99.94% yearly.
EPS Next Y10.66%
EPS Next 2Y49.14%
EPS Next 3Y33.36%
EPS Next 5Y22.56%
Revenue Next Year495.67%
Revenue Next 2Y345.1%
Revenue Next 3Y182.85%
Revenue Next 5Y99.94%

3.3 Evolution

ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. ACIU Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACIU. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACIU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • ACIU's earnings are expected to grow with 33.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.14%
EPS Next 3Y33.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACIU Dividend Analysis

5.1 Amount

  • ACIU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACIU Fundamentals: All Metrics, Ratios and Statistics

AC IMMUNE SA

NASDAQ:ACIU (3/18/2026, 2:55:37 PM)

3.15

-0.17 (-5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)04-28
Inst Owners25.85%
Inst Owner Change3.49%
Ins Owners3.4%
Ins Owner ChangeN/A
Market Cap320.58M
Revenue(TTM)N/A
Net Income(TTM)-71.87M
Analysts88
Price Target9.18 (191.43%)
Short Float %4.83%
Short Ratio9.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.03%
Min EPS beat(2)-18%
Max EPS beat(2)17.94%
EPS beat(4)3
Avg EPS beat(4)6.34%
Min EPS beat(4)-18%
Max EPS beat(4)17.94%
EPS beat(8)5
Avg EPS beat(8)-0.9%
EPS beat(12)8
Avg EPS beat(12)-64.44%
EPS beat(16)10
Avg EPS beat(16)-69.05%
Revenue beat(2)1
Avg Revenue beat(2)-11.08%
Min Revenue beat(2)-35.35%
Max Revenue beat(2)13.19%
Revenue beat(4)3
Avg Revenue beat(4)57.1%
Min Revenue beat(4)-35.35%
Max Revenue beat(4)200.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-6.69%
EPS NQ rev (3m)-6.69%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)-6.63%
Revenue NQ rev (3m)-8.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.66
P/FCF N/A
P/OCF N/A
P/B 4.04
P/tB 20.96
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.05
BVpS0.78
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.15%
Cap/Sales 20.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -3.24
F-Score2
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y10.66%
EPS Next 2Y49.14%
EPS Next 3Y33.36%
EPS Next 5Y22.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.27%
Revenue Next Year495.67%
Revenue Next 2Y345.1%
Revenue Next 3Y182.85%
Revenue Next 5Y99.94%
EBIT growth 1Y-95.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.24%
EBIT Next 3Y31.24%
EBIT Next 5Y-6.77%
FCF growth 1Y23.43%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y24.03%
OCF growth 3YN/A
OCF growth 5Y3.58%

AC IMMUNE SA / ACIU Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ACIU.


Can you provide the valuation status for AC IMMUNE SA?

ChartMill assigns a valuation rating of 1 / 10 to AC IMMUNE SA (ACIU). This can be considered as Overvalued.


How profitable is AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a profitability rating of 1 / 10.


What is the financial health of AC IMMUNE SA (ACIU) stock?

The financial health rating of AC IMMUNE SA (ACIU) is 2 / 10.


What is the expected EPS growth for AC IMMUNE SA (ACIU) stock?

The Earnings per Share (EPS) of AC IMMUNE SA (ACIU) is expected to grow by 10.66% in the next year.